Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Alprazitel - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Alprazitel

Approved

STANDARD

Alprazitel

Alpa Laboratories Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 06fd2a0add261b79
Company: Alpa Laboratories Limited
Type: Standard

Approval Details

Approval Id: 06fd2a0add261b79
Drug Approval Philippines Name: Alprazitel
Product Name: Alprazitel
Registration Number: DR-XY43622
Brand Name: Alprazitel
Generic Name: Praziquantel
Dosage Form: Tablet
Dosage Strength: 600mg
Manufacturer: Alpa Laboratories Limited
Trader: LOB International
Importer: Khriz Pharma Trading, Inc.
Distributor: Khriz Pharma Trading, Inc.
Issuance Date: 25 July 2024
Expiry Date: 12 August 2029
Pharmacologic Category: Anthelmintic
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

06fd2a0add261b79

Type

Standard

Back to Philippines FDA Approvals